A recently proposed research framework emphasizes biomarkers for amyloid, tau, and neurodegeneration (A,T,N) for diagnosis and staging of Alzheimer's Disease (AD) [1,2]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.